Ozempic and Wegovy, Novo Nordisk’s GLP-1 drugs that treat diabetes and obesity, are on the list. Astellas Pharma’s prostate cancer drug, Xtandi, is also on the list — alongside AstraZeneca’s cancer ...

Semaglutide sells for $997 a month when branded under Ozempic and $1,349 a month for Wegovy. The haircut to Ozempic may have a spillover effect on competitor drugs from Eli Lilly — Mounjaro and ...

As Medicare announced a fresh set of drugs selected for its price-setting process on Friday under the Inflation Reduction Act ...

On Friday, the U.S. Department of Health and Human Services (HHS) unveiled the selection of 15 additional drugs covered under ...

Shares of GSK PLC GSK inched up 0.78% to £13.59 Friday, on what proved to be an all-around great trading session for the ...

Medicare has announced 15 new drugs up for price negotiations, set to begin in the next several months with top drugmakers, ...

Accounting for around one-quarter of Europe's market cap, the GRANOLAS members are: GSK (GSK) (UK:GSK), Roche (CH:ROG), ASML (ASML) (NL:ASML), Nestlé (CH:NESN) (NSRGY), Novartis (NVS) (CH:NOVN), Novo ...

The U.S. government targets 15 high-cost medications for Medicare price negotiations for 2027, under the Inflation Reduction ...

The U.S. government has selected the second batch of drugs up for Medicare price negotiations under the Inflation Reduction ...

The Department of Health and Human Services, through the Centers for Medicare & Medicaid Services, announced the selection of 15 additional ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

Novo Nordisk's Ozempic and Wegovy are among 15 drugs targeted for Medicare price negotiations in 2027. The U.S. aims to cut ...